Study to Evaluate the Benefits for the Patient Associated With the Treatment of Plaque Psoriasis With Apremilast After Other Systemic Treatment in Conditions of Clinical Practice in Spain (APPROPIATE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03539419|
Recruitment Status : Recruiting
First Posted : May 28, 2018
Last Update Posted : November 21, 2018
Observational, prospective and multicenter study in approximately 30 sites nationwide. The investigators participating in this study will be dermatologists specializing in this pathology.
The present study will include adult patients with moderate to severe plaque who have started apremilast treatment for first time 3 months (+/- 4 weeks) before their inclusion in the study, according to the specifications of the drug's prescribing information and under usual clinical practice. Recruitment will be consecutive and the reason for not including a potential candidate patient will be registered. The decision to prescribe apremilast treatment should be clearly dissociated from the inclusion of the patient in the study. Therefore, the choice of the therapeutic strategy will be made independently by the physician.
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||150 participants|
|Official Title:||PROSPECTIVE OBSERVATIONAL STUDY TO EVALUATE THE BENEFITS FOR THE PATIENT ASSOCIATED WITH THE TREATMENT OF PLAQUE PSORIASIS WITH APREMILAST AFTER OTHER SYSTEMIC TREATMENTS IN CONDITIONS OF CLINICAL PRACTICE IN SPAIN (APPROPRIATE Study)|
|Actual Study Start Date :||June 12, 2018|
|Estimated Primary Completion Date :||July 25, 2019|
|Estimated Study Completion Date :||July 25, 2020|
Patients with plaque psoriasis on apremilast
Adult patients with moderate to severe plaque who have started apremilast treatment for first time 3 months (+/- 4 weeks) before their inclusion in the study, according to the specifications of the drug's prescribing information and under usual clinical practice.
- Percentage of subjects achieving PBI ≥ 1 [ Time Frame: Approximately 7 months ]Patient Benefit Index (PBI) is a measure of the benefit associated with a patient-reported treatment consisting of the administration of two questionnaires: the Patient needs questionnaire (PNQ), administered at baseline, and the patient benefit questionnaire (PBQ), administered during treatment
- Describe the persistence of apremilast treatment [ Time Frame: Approximately 7 months ]Is defined as the duration of time from initiation to discontinuation of therapy.
- Describe changes in the perception of pruritus intensity during apremilast treatment in patients with moderate to severe plaque psoriasis [ Time Frame: Approximately 13 months ]Pruritus intensity measures: Usually used scales are based on patient perception: Visual analogue scale (VAS). Horizontal line of 100 mm, with descriptive signs at the ends indicating "no itching" and "the worst imaginable itch". The score is obtained by measuring the distance in millimeters from the beginning of the line to a vertical mark placed by the patient to indicate the intensity of the pain
- Describe the changes in the quality of life associated with treatment with apremilast [ Time Frame: Approximately 13 months ]The information on the variables studied will be obtained from the clinical record and the tests and evaluations carried out routinely during the patient follow-up who initiate a first treatment with apremilast, as well as the questionnaires for the evaluation of the dermatological quality of life (DLQI self-administered questionnaire), the evaluation of treatment satisfaction reported by the patient (PBI) and the intensity of pruritus (self-reported measures, VAS).
- Describe the percentage of patients with moderate to severe plaque psoriasis who achieve a relevant minimum clinical benefit, defined as PBI ≥ 1 [ Time Frame: Approximately 13 months ]Patient Benefit Index (PBI) is a measure of the benefit associated with a patient-reported treatment consisting of the administration of two questionnaires: the Patient needs questionnaire (PNQ), administered at baseline, and the patient benefit questionnaire (PBQ), administered during treatment.
- Describe changes in concomitant medication associated with management of moderate to severe plaque psoriasis during apremilast treatment [ Time Frame: Approximately 13 months ]Describe changes of concomitant medication specific for psoriasis associated to apremilast treatment indicating the date of beginning and end of the concomitant treatments that the patient receives during the treatment with apremilast.
- Describe changes in cutaneous involvement of patients with psoriasis in severe intensity plaques that change to moderate intensity [ Time Frame: Approximately 13 months ]A patient with moderate-intensity psoriasis will be considered if he/she has PASI 7-15 and DLQI scores ≤ 15, or PASI scores <7 and DLQI ≥ 5 at the time of starting apremilast treatment. (Patients with PASI 7-15 and DLQI> 15 scores and presenting cutaneous lesions in locations that are difficult to access for treatment or that have a significant psychosocial impact may be classified as moderate or severe psoriasis cases according to the investigators' criteria.) In this subgroup of patients will estimate the proportion of patients with moderate-intensity psoriasis who change to mild intensity.
- Adverse Events (AEs) [ Time Frame: Approximately 13 months ]Number of subjects with adverse event. Safety and tolerability to treatment will be assessed by the collection of adverse events (AE) occurring during follow-up.
- Clinical and demographic characteristics of plaque psoriasis patients: Body surface affected (BSA). [ Time Frame: Approximately 7 months ]Psoriasis is characterized as mild, moderate, or severe according to the amount of body surface area (BSA) affected and the severity of redness, thickness, and scaling of the skin. According to the centers usual clinical practice, the clinical assessment of psoriatic disease is based on the BSA. Percentage of body surface affected by psoriasis (scale 0-100).
- Clinical and demographic characteristics of plaque psoriasis patients: Physician Global Assessment (PGA). [ Time Frame: Approximately 7 months ]The Psoriasis Global Assessment (PGA) of improvement (or Physician's global assessment of improvement) measure the global assessment of the patient's overall severity of the disease on a 6-point scale, scored from "severe" to "clear".
- Clinical and demographic characteristics of plaque psoriasis patients: PGA x BSA [ Time Frame: Approximately 7 months ]Commonly used instruments for measuring psoriasis, such as Psoriasis Area and Severity Index (PASI), have limitations, including high complexity. PGAxBSA is a simple and sensitive instrument for measuring psoriasis severity. PGA×BSA is practical alternative to PASI for measuring severity and treatment response
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03539419
|Contact: Associate Director Clinical Trial Disclosureemail@example.com|
|Hospital Juan Ramón Jiménez||Not yet recruiting|
|Huelva, Andalucia, Spain, 50009|
|Complejo Hospitalario de Jaén||Not yet recruiting|
|Jaen, Andalucía, Spain, 23007|
|Hospital Carlos Haya||Not yet recruiting|
|Malaga, Andalucía, Spain, 29010|
|Hospital Universitario Marqués de Valdecilla||Not yet recruiting|
|Santander, Cantabria, Spain, 39008|
|Hospital Nuestra Señora de Sonsoles||Not yet recruiting|
|Avila, Castilla-León, Spain, 05004|
|Hospital Universitario Río hortega de Valladolid||Not yet recruiting|
|Valladolid, Castilla-León, Spain, 47012|
|Hospital del Mar||Not yet recruiting|
|Barcelona, Cataluña, Spain, 08003|
|Hospital Sant Pau||Not yet recruiting|
|Barcelona, Cataluña, Spain, 08026|
|Hospital Valle Hebrón||Not yet recruiting|
|Barcelona, Cataluña, Spain, 08035|
|Hospital de Bellvitge||Not yet recruiting|
|Barcelona, Cataluña, Spain, 08907|
|Hospital General de Alicante||Not yet recruiting|
|Alicante, Comunidad Valenciana, Spain, 03010|
|Hospital Clínico Valencia||Not yet recruiting|
|Valencia, Comunidad Valenciana, Spain, 46010|
|Hospital General Valencia||Not yet recruiting|
|Valencia, Comunidad Valenciana, Spain, 46014|
|Hospital La Fe Valencia||Recruiting|
|Valencia, Comunidad Valenciana, Spain, 46026|
|Hospital Infanta Cristina Badajoz||Not yet recruiting|
|Badajoz, Extremadura, Spain, 06080|
|Hospital Universitario de Pontevedra||Not yet recruiting|
|Pontevedra, Galicia, Spain, 36164|
|Hospital Dr Negrin||Not yet recruiting|
|Las Palmas de Gran Canaria, Islas Canarias, Spain, 35010|
|Hospital Universitario de Canarias||Not yet recruiting|
|Santa Cruz de Tenerife, Islas Canarias, Spain, 38320|
|Hospital Santa Lucía||Not yet recruiting|
|Cartagena, Murcia, Spain, 30202|
|Hospital La Princesa||Not yet recruiting|
|Madrid, Spain, 28006|
|Hospital Infanta Leonor||Not yet recruiting|
|Madrid, Spain, 28031|
|Hospital Universitario Puerta del Hierro||Not yet recruiting|
|Madrid, Spain, 28222|
|Hospital de Móstoles||Not yet recruiting|
|Madrid, Spain, 28933|
|Hospital Clínico de Zaragoza||Not yet recruiting|
|Zaragoza, Áragon, Spain, 50009|
|Hospital Miguel Servet||Not yet recruiting|
|Zaragoza, Áragon, Spain, 50009|
|Study Director:||Carmen García, Senior Advocacy RML||Celgene Corporation|